← back to search

Zheng Zhu

Xijing Hospital · US
Area of research
Molecular Biology · Surgery
Research interest
Research interests include RNA modifications and cancer, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer Genomics and Diagnostics, and Nanoplatforms for cancer theranostics.
h-index
29
citations
3,183
works
133
NIH funding
primary concept
Medicine
email

Recent publications

A Manganese‐Based Nanodriver Coordinates Tumor Prevention and Suppression through STING Activation in Glioblastoma
Advanced Healthcare Materials 2024cited by 23position: middledoi
A transformable nanoplatform with multiple therapeutic and immunostimulatory properties for treatment of advanced cancers
Biomaterials 2023cited by 28position: middledoi
1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)
Annals of Oncology 2023cited by 22position: lastdoi
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Journal of Experimental & Clinical Cancer Research 2022cited by 618position: lastdoi
Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis
Cancer Immunology Research 2022cited by 77position: middledoi
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Journal for ImmunoTherapy of Cancer 2021cited by 80position: middledoi
Targeting ferroptosis-based cancer therapy using nanomaterials: strategies and applications
Theranostics 2021cited by 79position: middledoi
Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor
Cancer Cell International 2020cited by 42position: middledoi
Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials
ACS Nano 2020cited by 35position: middledoi
Odanacatib, A Cathepsin K‐Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases
Journal of Periodontology 2015cited by 51position: middledoi
A Small Molecule, Odanacatib, Inhibits Inflammation and Bone Loss Caused by Endodontic Disease
Infection and Immunity 2015cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Chong-xian Pan · University of California, Davis3 papers (2021–2023) · 2 papers (2021–2022)Lianxiang Luo · Macau University of Science and Technology2 papers (2020–2021)Yuanpei Li · University of California, Davis2 papers (2020–2023)Longmeng Li · University of California, Davis2 papers (2020–2023)Riming Huang · California Institute of Technology2 papers (2020–2021)Liang Hao · Peking University2 papers (2015–2015)Lu Zhang · Hebei Agricultural University2 papers (2020–2024)Dalin Zhang · University of California, Davis2 papers (2020–2023)Michael S. Reddy · University of California, San Francisco2 papers (2015–2015)Shaoming Zhu · University of California, Davis1 papers (2021–2021)Wenwu Xiao · University of California, Davis1 papers (2020–2020)John D. Mountz · University of Alabama at Birmingham1 papers (2015–2015)Liejing Lu · Sun Yat-sen University1 papers (2024–2024)Yue Song · Southern University of Science and Technology1 papers (2024–2024)K. Wang · Union Hospital1 papers (2023–2023)Xingjian Yu · National University of Singapore1 papers (2020–2020)Tatu Rojalin · University of California, Davis1 papers (2020–2020)Kit S. Lam · UC Davis Comprehensive Cancer Center1 papers (2020–2020)Fu‐An Deng · Southern University of Science and Technology1 papers (2024–2024)